042. Denosumab-associated osteonecrosis of the jaw in NSCLC patient: a case report

Efimia Boutsikou, Stergios Dalampiras,Paul Zarogoulidis,Dionysios Spyratos,Konstantinos Porpodis,Ellada Eleptheriadou,Konstantinos Zarogoulidis

Journal of Thoracic Disease（2015）

引用 0|浏览2

暂无评分

摘要

Background Osteonecrosis of the jaw (ONJ) following bisphosphonate use is well documented. However, to our knowledge, there are few cases reported on ONJ related to the use of other pharmaceutical agents, such as denosumab—a receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor that has recently been approved for the prevention of SRE in patients with osteoporosis and solid tumors with metastases to bone.

查看译文

关键词

Osteonecrosis of the Jaw,Osteonecrosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要